AU2002338528B2 - Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use - Google Patents

Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use Download PDF

Info

Publication number
AU2002338528B2
AU2002338528B2 AU2002338528A AU2002338528A AU2002338528B2 AU 2002338528 B2 AU2002338528 B2 AU 2002338528B2 AU 2002338528 A AU2002338528 A AU 2002338528A AU 2002338528 A AU2002338528 A AU 2002338528A AU 2002338528 B2 AU2002338528 B2 AU 2002338528B2
Authority
AU
Australia
Prior art keywords
nitric oxide
hypertension
compound
nitrosated
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002338528A
Other languages
English (en)
Other versions
AU2002338528A1 (en
Inventor
David S. Garvey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Nicox SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox SA filed Critical Nicox SA
Publication of AU2002338528A1 publication Critical patent/AU2002338528A1/en
Application granted granted Critical
Publication of AU2002338528B2 publication Critical patent/AU2002338528B2/en
Priority to AU2008201838A priority Critical patent/AU2008201838B2/en
Assigned to NICOX S.A. reassignment NICOX S.A. Request for Assignment Assignors: NITROMED, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)
  • Pyrane Compounds (AREA)
AU2002338528A 2001-05-02 2002-05-01 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use Ceased AU2002338528B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008201838A AU2008201838B2 (en) 2001-05-02 2008-04-23 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28772501P 2001-05-02 2001-05-02
US60/287,725 2001-05-02
PCT/US2002/013667 WO2002087508A2 (en) 2001-05-02 2002-05-01 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008201838A Division AU2008201838B2 (en) 2001-05-02 2008-04-23 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use

Publications (2)

Publication Number Publication Date
AU2002338528A1 AU2002338528A1 (en) 2003-04-17
AU2002338528B2 true AU2002338528B2 (en) 2008-01-24

Family

ID=23104065

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002338528A Ceased AU2002338528B2 (en) 2001-05-02 2002-05-01 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use

Country Status (8)

Country Link
US (2) US7138430B2 (cg-RX-API-DMAC7.html)
EP (1) EP1406608B1 (cg-RX-API-DMAC7.html)
JP (2) JP2004528337A (cg-RX-API-DMAC7.html)
AT (1) ATE437637T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002338528B2 (cg-RX-API-DMAC7.html)
CA (1) CA2446064A1 (cg-RX-API-DMAC7.html)
DE (1) DE60233140D1 (cg-RX-API-DMAC7.html)
WO (1) WO2002087508A2 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
JP2007502831A (ja) * 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
US7754500B2 (en) 2003-11-21 2010-07-13 Anp Technologies, Inc. Asymmetrically branched polymer conjugates and microarray assays
US20090131342A1 (en) * 2004-01-22 2009-05-21 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
WO2005102304A1 (en) * 2004-04-23 2005-11-03 Northern Sydney And Central Coast Area Health Service Methods and compositions for the treatment of myocardial conditions
US7838552B2 (en) * 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
WO2006025070A2 (en) 2004-07-30 2006-03-09 Torrent Pharmaceuticals Limited Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
CA2576255A1 (en) * 2004-08-09 2006-02-16 Universite Catholique De Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
NZ560386A (en) * 2005-01-31 2009-12-24 Mylan Lab Inc Pharmaceutical composition comprising hydroxylated nebivolol
WO2006083780A2 (en) * 2005-01-31 2006-08-10 Mylan Laboratories, Inc. Glucuronidated nebivolol
US20060222592A1 (en) * 2005-04-05 2006-10-05 Clemens Burda Nanoparticles and methods of manufacturing nanoparticles for electronic and non-electronic applications
CA2606815C (en) 2005-05-02 2017-03-07 Anp Technologies, Inc. Polymer conjugate enhanced bioassays
NZ563759A (en) * 2005-05-31 2010-06-25 Mylan Lab Inc Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate
RU2441653C2 (ru) * 2005-05-31 2012-02-10 Милан Лэборетериз, Инк. Композиции, содержащие небиволол
US20090253662A1 (en) * 2005-10-04 2009-10-08 Nitromed, Inc. Genetic risk assessment in heart failure: impact of genetic variation of aldosterone synthase promoter polymorphism
US20070154466A1 (en) * 2005-12-30 2007-07-05 Jan Weber Internal medical devices containing peroxide-converting catalysts
US20080193385A1 (en) * 2007-02-08 2008-08-14 Todd Maibach Compositions and methods for treating neuropathy
CA2599082A1 (en) * 2007-08-27 2009-02-27 Ping I. Lee Supramacromolecular polymer complexes providing controlled nitric oxide release for healing wounds
WO2009026697A1 (en) * 2007-08-28 2009-03-05 University Of Manitoba A method of reducing a vasodilatory response using a guanylate cyclase pathway inhibitor or an h2o2 reducing agent
TW200918099A (en) 2007-09-14 2009-05-01 Nitto Denko Corp Drug carriers
CA2732513C (en) 2008-08-01 2017-04-25 Arca Biopharma, Inc. Methods and compositions involving (s)-bucindolol
HUP0800498A2 (en) * 2008-08-06 2010-03-29 Semmelweis Egyetem Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
US11207109B2 (en) 2010-10-20 2021-12-28 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
CN102977068A (zh) * 2012-05-03 2013-03-20 中国药科大学 一氧化氮供体型异色满酮类衍生物、其制备方法及用途
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
EP2946213B1 (en) * 2013-01-18 2023-05-24 synlab Services GmbH Prediction of kidney disease progression using homoarginine as a biomarker
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
JP7002451B2 (ja) 2015-12-15 2022-01-20 ニオバスク ティアラ インコーポレイテッド 経中隔送達システム
CN108882981B (zh) 2016-01-29 2021-08-10 内奥瓦斯克迪亚拉公司 用于防止流出阻塞的假体瓣膜
US11173235B2 (en) 2016-07-15 2021-11-16 Cook Regentec Llc Nitrite eluting devices and methods of use thereof
US11096781B2 (en) 2016-08-01 2021-08-24 Edwards Lifesciences Corporation Prosthetic heart valve
CN110198728A (zh) 2016-11-17 2019-09-03 莱诺翁股份有限公司 用谷胱甘肽组合物治疗呼吸道疾病和感染
AU2017361296B2 (en) 2016-11-21 2022-09-29 Neovasc Inc. Methods and systems for rapid retraction of a transcatheter heart valve delivery system
EP3672530A4 (en) 2017-08-25 2021-04-14 Neovasc Tiara Inc. SEQUENTIALLY INSERTED TRANSCATHETER MITRAL VALVE PROSTHESIS
CN111615395B (zh) 2017-11-17 2024-08-06 莱诺翁股份有限公司 稳定的抗坏血酸组合物及其使用方法
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
MX2020012717A (es) 2018-05-25 2021-07-15 Arca Biopharma Inc Métodos y composiciones con bucindolol para el tratamiento de la fibrilación auricular.
AU2019374743B2 (en) 2018-11-08 2022-03-03 Neovasc Inc. Ventricular deployment of a transcatheter mitral valve prosthesis
CN113747863B (zh) 2019-03-08 2024-11-08 内奥瓦斯克迪亚拉公司 可取回假体递送系统
AU2020256195B2 (en) 2019-04-01 2022-10-13 Neovasc Inc. Controllably deployable prosthetic valve
US11491006B2 (en) 2019-04-10 2022-11-08 Neovasc Tiara Inc. Prosthetic valve with natural blood flow
CA3282225A1 (en) 2019-05-20 2026-03-02 Neovasc Tiara Inc. Introducer with hemostasis mechanism
JP7520897B2 (ja) 2019-06-20 2024-07-23 ニオバスク ティアラ インコーポレイテッド 薄型人工補綴僧帽弁
CA3199943A1 (en) 2020-08-24 2022-03-03 Edwards Lifesciences Corporation Balloon cover for a delivery apparatus for an expandable prosthetic heart valve
WO2022198259A1 (en) * 2021-03-25 2022-09-29 The Heart Research Institute Ltd Treatment methods for pulmonary arterial hypertension
KR20240131358A (ko) 2022-01-04 2024-08-30 레노비온, 아이엔씨. 글루타치온 염을 포함하는 수용액

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012584A2 (en) * 1999-08-12 2001-02-22 Nicox S.A. Pharmaceutical compounds
US6635273B1 (en) * 1999-10-29 2003-10-21 Trustees Of Boston University Methods of treating vascular diseases characterized by nitric oxide insufficiency

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US311175A (en) 1885-01-27 And joseph l
US4654362A (en) * 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
US4868179A (en) 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
CA1337432C (en) 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
US5428061A (en) 1988-09-15 1995-06-27 Schwarz Pharma Ag Organic nitrates and method for their preparation
US5284872A (en) 1989-09-12 1994-02-08 Schwarz Pharma Ag Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
DK0676964T3 (da) 1991-11-14 2001-02-05 Brigham & Womens Hospital Nitrosylering af enzym-SH-grupper som en terapeutisk modalitet
US5650447A (en) 1992-08-24 1997-07-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitric oxide-releasing polymers to treat restenosis and related disorders
US5910316A (en) 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
DE4321306A1 (de) 1993-06-26 1995-01-05 Sanol Arznei Schwarz Gmbh Disulfide
TW355683B (en) 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
HU226208B1 (en) 1994-12-28 2008-06-30 Janssen Pharmaceutica Nv Use of nebivolol for producing anti-atherogenic pharmaceuticals
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5932538A (en) 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US5807847A (en) 1996-06-04 1998-09-15 Queen's University At Kingston Nitrate esters
CA2270118A1 (en) 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292426B1 (it) 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
EP1000023B1 (en) 1997-07-03 2011-02-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
IT1301759B1 (it) 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
AU3703900A (en) 1999-02-24 2000-09-14 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
AU3713600A (en) 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
IT1308633B1 (it) 1999-03-02 2002-01-09 Nicox Sa Nitrossiderivati.
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1311921B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1311923B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
IT1320176B1 (it) 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
JP2007513113A (ja) 2003-12-02 2007-05-24 ニコックス エス エイ 抗高血圧薬剤のニトロオキシ誘導体
DK1691804T3 (da) 2003-12-02 2007-07-16 Nicox Sa Nitrooxydderivater af carvedilol og andre beta-blokkere som antihypertensive lægemidler

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012584A2 (en) * 1999-08-12 2001-02-22 Nicox S.A. Pharmaceutical compounds
US6635273B1 (en) * 1999-10-29 2003-10-21 Trustees Of Boston University Methods of treating vascular diseases characterized by nitric oxide insufficiency

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cardiovascular Research, 2001, 49(2), pp 430-9 *
Hypertension, 1999, 3(III), pp467-71 *

Also Published As

Publication number Publication date
EP1406608A4 (en) 2004-10-20
EP1406608A2 (en) 2004-04-14
US20040132805A1 (en) 2004-07-08
JP2010248226A (ja) 2010-11-04
US7138430B2 (en) 2006-11-21
WO2002087508A3 (en) 2003-12-11
WO2002087508A2 (en) 2002-11-07
US20060009513A1 (en) 2006-01-12
US7384976B2 (en) 2008-06-10
JP2004528337A (ja) 2004-09-16
DE60233140D1 (de) 2009-09-10
EP1406608B1 (en) 2009-07-29
CA2446064A1 (en) 2002-11-07
ATE437637T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
US7384976B2 (en) Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use
AU2002338528A1 (en) Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
JP2004528337A5 (cg-RX-API-DMAC7.html)
US7537785B2 (en) Composition for treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
EP1301500B1 (en) Nitrosated and nitrosylated taxanes, compositions and methods of use
AU2001259399B2 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20100068267A1 (en) Compositions for treating vascular diseases characterized by nitric oxide insufficiency
US7345053B2 (en) Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
AU780261B2 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU2001259399A1 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
CA2518506A1 (en) Nitrosated and nitrosylated compounds, compositions and methods of use
JP2007502831A (ja) ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
US8614228B2 (en) Quinone prodrug compositions and methods of use
AU2008201838B2 (en) Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
JP2008535858A (ja) 心不全における遺伝リスク、すなわちnos3の遺伝子変異の影響の評価方法
JP2013507325A (ja) 酸化窒素含有ジヒドロリポ酸及びその治療用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NICOX S.A.

Free format text: FORMER OWNER WAS: NITROMED, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired